GNA Biosolutions GmbH (GNA), a Munich, Germany-based manufacturer of ultrafast pathogen diagnostic instruments, raised €6m in Series B financing round.
The round was led by Robert Bosch Venture Capital (RBVC), with participation from SHS Gesellschaft für Beteiligungsmanagement GmbH, b-to-v Partners, and UnternehmerTUM-Fonds and existing shareholders Mey Capital Matrix and KfW.
The company intends to use the funds to bring its first product, the Pharos400 instrument, to market maturity.
Founded in 2010 and led by Drs. Lars Ullerich, Federico Bürsgens and Joachim Stehr, GNA works with a laser-based PCR process to facilitate reliable pathogen detection. The technology enables physicians and hospitals to diagnose bacterial diseases within minutes, with no need for time-consuming laboratory diagnostics. The specific DNA sequences for the pathogen under investigation are extracted and artificially multiplied (Polymerase Chain Reaction = PCR). The laser component of the technology is used for the necessary PCR thermo-cycling process (sample heating and cooling) and to read out results.
The company was spun-out of the Institute for Photonics and Optoelectronics at Ludwig-Maximilians-Universität, Munich, in 2010.